A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results-Reference-Cited by-同舟云学术

A phase I dose escalation and expansion trial of the next-generation oral SERD camizestrant in women with ER-positive, HER2-negative advanced breast cancer: SERENA-1 monotherapy results

Published:2024-08 Issue:8 Volume:35 Page:707-717
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Hamilton E.,Oliveira M.,Turner N.,García-Corbacho J.,Hernando C.,Ciruelos E.M.,Kabos P.,Ruiz-Borrego M.,Armstrong A.,Patel M.R.,Vaklavas C.,Twelves C.,Boni V.,Incorvati J.,Brier T.,Gibbons L.,Klinowska T.,Lindemann J.P.O.,Morrow C.J.,Sykes A.,Baird R.D.

Funder

AstraZeneca plc

Publisher

Elsevier BV

Reference33 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Cancer statistics, 2023;Siegel;CA Cancer J Clin,2023

3. Breast cancer statistics, 2022;Giaquinto;CA Cancer J Clin,2022

4. Breast Cancer Facts & Figures 2022-2024,2022

5. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer;Jeselsohn;Nat Rev Clin Oncol,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Oral SERDs changing the scenery in hormone receptor positive breast cancer, a comprehensive review;Cancer Treatment Reviews;2024-09

2. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer;Nature Reviews Clinical Oncology;2024-08-23

3. The new oral SERDs in endocrine-resistant breast cancer: who will benefit the most?;Annals of Oncology;2024-08